Highlights
- Revenue from product sales up 25% to $804k, total revenue $1.46 million
- Revenue growth driven by sales of new IVD test through distribution partner StatLab, in first four months since commercial launch
- Recent ASX listing provides capital to drive US sales growth and geographic expansion for the hTERT test, as well as future product development to expand the products’ use beyond the current application in bladder cancer
31 August 2017: Sienna Cancer Diagnostics, (ASX:SDX) a commercial stage, medical technology company focused on the development and commercialisation of innovative cancer-related tests for the diagnostic pathology market, releases its Appendix 4E and Financial Report for the period ended 30 June 2017. These are the first financial results published by the company since listing on the Australian Securities Exchange in August 2017.
For further information please download PDF attached:
Download this document
